Lesson 19 of 20
【Capstone lab】 Who can see this fragment?
Redrawing lesson 7's picture from scratch · and who that picture erased
Last lab. It gathers the previous eighteen lessons into one question.
If you build a therapy against this fragment, how many people can use it?
Three pieces are needed.
| What we need | Where from | Which lesson |
|---|---|---|
| Which plate this fragment rides on | VDJdb | 7 |
| What share of people carry that plate | cited population frequencies | this one |
| Whether a different plate really means not seeing it | the polymorphism of lessons 8 and 9 | 8 |
Let us stack them in order.
The same skew as lesson 7. This time we attach people to it.
Python
Runs in your browser
A person carries two HLA-A copies, so 'people carrying' exceeds the allele frequency.
Python
Runs in your browser
This is why TCR therapy starts at A*02:01, and why stopping there is not acceptable.
Python
Runs in your browser
It shows how coarse a single line of 'A*02 positive' is as a trial criterion.
Python
Runs in your browser
So what this one picture says
This is the shape of the table
More than half the records pile onto one plate. Most of the 1,946
fragments are things loaded on A*02:01.
This is the shape of people
About a quarter carry A*02:01 — and that share varies widely by
ancestry.
So here is the work
Somebody has to run experiments finding fragments on the
less-studied plates. More algorithm will not do it — what is not in the table cannot be
computed out of it.
This is where lesson 6's sentence arrives. The skew of this table is the skew of researchers, not of the immune system. And that skew is not merely a statistical matter; it becomes a question of who gets treated.
🤔 Check yourself
A*02:01 alone covers well under half of people. Why is it more than half the table?
Answer Tetramers, cell lines and prior papers are all already set up for A*02:01, so the next experiment starts there.
🤔 Check yourself
What goes wrong when you multiply and add coverage across several alleles?
Answer They sit close together on chromosome 6 and travel as a block. Our figure is an optimistic upper bound.
🤔 Check yourself
What is the risk of using 'A*02 positive' as a trial criterion?
Answer Only the first field of the name matches. The groove the fragment sits in may not.